4 results
8-K
EX-99.1
VSTM
Verastem Inc
9 Apr 24
Delivering Novel Therapies in RAS/MAPK Pathway Driven Cancers April 2024 Corporate Presentation
5:10pm
Dose Intensity 83% ± 20% 29 patients were evaluable for efficacy with a minimum follow - up of 12 months and 13 (45%) patients remain on study treatment
8-K
EX-99.1
VSTM
Verastem Inc
12 Sep 23
Corporate Presentation September 2023
4:08pm
% (4/14) Tumor shrinkage, % (n) 86% (25) Median Time to Response 5.5 months (range 1.6-14.7 months) Relative Dose Intensity 83% ± 20% 29 patients were … ) 86% (25) Median Time to Response 5.5 months (range 1.6-14.7 months) Relative Dose Intensity 83% ± 20% 29 patients were evaluable for efficacy
8-K
EX-99.1
VSTM
Verastem Inc
8 Jun 23
Corporate Presentation June 2023
5:24pm
) Relative Dose Intensity 83% ± 20% 29 patients were evaluable for efficacy with a minimum follow - up of 12 months and 13 (45%) patients remain on study … ) Median Time to Response 5.5 months (range 1.6 - 14.7 months) Relative Dose Intensity 83% ± 20% 29 patients were evaluable for efficacy with a minimum
- Prev
- 1
- Next